- Home
- QNRX
as 10-24-2025 3:56pm EST
Quoin Pharmaceuticals Ltd is a clinical stage specialty pharmaceutical company focused on developing and commercializing therapeutic products that treat rare and orphan diseases. Its pipeline comprises three products that collectively have the potential to target a broad number of rare and orphan indications, including Netherton Syndrome, Peeling Skin Syndrome, Palmoplantar Keratoderma, Epidermolysis Bullosa, and others.
| Founded: | 2018 | Country: | United States |
| Employees: | N/A | City: | KFAR SABA |
| Market Cap: | 4.8M | IPO Year: | N/A |
| Target Price: | N/A | AVG Volume (30 days): | 833.0K |
| Analyst Decision: | N/A | Number of Analysts: | N/A |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -32.59 | EPS Growth: | N/A |
| 52 Week Low/High: | $5.01 - $48.30 | Next Earning Date: | 11-07-2025 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Stock Insider Trading Activity of Quoin Pharmaceuticals Ltd. (QNRX)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| LANGER DENNIS | QNRX | Director | Oct 14 '25 | Buy | $8.49 | 15,152 | $128,640.48 | 15,153 |
Latest Quoin Pharmaceuticals Ltd. News
QNRX Breaking Stock News: Dive into QNRX Ticker-Specific Updates for Smart Investing
GlobeNewswire
4 days ago
Quoin Pharmaceuticals Announces U.S. FDA Grants Orphan Drug Designation for QRX003 in Netherton Syndrome
MT Newswires
12 days ago
Top Premarket Decliners
MT Newswires
15 days ago
Top Midday Gainers
MT Newswires
15 days ago
Quoin Pharmaceuticals Shares Jump After Announcing $104.5 Million Private Placement
GlobeNewswire
15 days ago
Quoin Pharmaceuticals Announces Private Placement Financing of Up to $104.5 Million
GlobeNewswire
2 months ago
Quoin Pharmaceuticals Releases Fifth NETHERTON NOW Video Featuring Writers and Influencers Allie and Kaleigh Fasanella, Twin Sisters Living with Netherton Syndrome
GlobeNewswire
4 months ago
Quoin Pharmaceuticals Releases New NETHERTON NOW Video Featuring Professor Jemima Mellerio, International Expert in Genetic Skin Diseases
GlobeNewswire
4 months ago
Quoin Pharmaceuticals Announces FDA Grants Rare Pediatric Disease Designation for QRX003 in Netherton Syndrome
Compare QNRX vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "QNRX Quoin Pharmaceuticals Ltd. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.